The United Kingdom and the United States have reached a landmark bilateral deal that will maintain no levies on British medicine exports going into the US market.
Agreement Details of the Pact
As part of the deal, the UK has agreed to raise spending on pharmaceuticals through the public health system. This move ensures that tariffs on these crucial goods will remain at nothing for a timeframe of three years.
This deal follows previous threats to significantly raise duties on branded drug imports, with potential rates discussed reaching one hundred percent.
"This deal with the Britain strengthens the worldwide climate for innovative medicines and establishes much-needed balance to American-British pharmaceutical trade," a release noted.
Trade Impact
Drugs constitute one of the Britain's most significant exports to the America, which is by far the biggest destination for major companies like GSK and AstraZeneca.
Trade data indicate that in the year prior to the third quarter, the UK sold medicines worth over eleven billion pounds to the US. This figure made up 17.4% of total UK exports in that span.
"This deal safeguards employment, stimulates capital expenditure and sets the stage for the UK to emerge as a global hub for life sciences," a minister remarked.
Specific NHS Changes
The pact entails several notable changes from the UK:
- Revised Affordability Limit: The UK will increase the cost ceiling at which it judges new treatments to be too expensive by 25%.
- Boosted Medicine Funding: There is a goal to increase total health service expenditure on drugs from 0.3 percent of the national economy to 0.6% over the following ten-year period.
- Payback Limit: The amount manufacturers must refund to the NHS to control costs will be limited at fifteen percent. Last year, rebates topped 20%.
Recent Tensions
The pact follows a protracted row between the drug companies and the ministers over medicine costs and NHS adoption.
These tensions were intensified by claims that US patients were paying a premium for the same drugs than consumers in the UK and Europe.
In recent months, several large drug company projects in the UK have been delayed or abandoned, while substantial funding commitments have been pledged toward projects in the United States.
A senior figure publicly accepted that the NHS had to increase expenditure on drugs, noting that its budget allocation on drugs had shrunk as a proportion of its resources over the previous ten-year period.
